{"entity":{"id":"william-wierda","kind":"person","name":"William G. Wierda","aka":[],"tldr":"Led CAPTIVATE, which established fixed-duration ibrutinib plus venetoclax as a first-line option for CLL.","summary":"William Wierda was principal investigator of CAPTIVATE, the trial showing fixed-duration ibrutinib plus venetoclax produces high rates of undetectable MRD and durable remissions in untreated CLL and led to its approval in Europe, and led the MRD-guided cohort of that study. He chairs the NCCN CLL guidelines panel and helped develop the MD Anderson prognostic nomogram for CLL.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wierda%20WG%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"tags":["cll","fixed-duration","guidelines"],"related":[],"cancers":["cll"],"sections":[],"technologies":["mrd-testing","kinase-inhibitors"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":["captivate"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Section Chief of CLL, Department of Leukemia, MD Anderson Cancer Center","institutionId":"md-anderson","specialisms":["Chronic lymphocytic leukaemia","Fixed-duration targeted therapy","MRD-guided treatment","Guidelines"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wierda%20WG%5BAuthor%5D%20chronic%20lymphocytic%20leukemia"}],"papers":[{"title":"Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.00807"},{"title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","journal":"Blood","year":2022,"doi":"10.1182/blood.2021014488"}],"orcid":"0000-0002-7357-270X"},"route":"/people/william-wierda/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"}],"drug":[{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/"}],"trial":[{"id":"captivate","kind":"trial","name":"CAPTIVATE","route":"/trials/captivate/"}]}}